secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001815776-24-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics files NDA for LNZ100, reports Q2 net loss $10.3M, raises $30M via PIPE
--------------------------------------------------------------------------------

- NDA submitted to FDA for LNZ100 aceclidine eye drop for presbyopia, supported by positive Phase 3 CLARITY data.
- Q2 net loss $10.3M ($0.40/share) vs $14.7M ($7.53) in Q2 2023; R&D expenses fell to $6.9M from $12.6M.
- Cash, equivalents and securities $196.2M; pro forma after July $30M Ridgeback PIPE, $226.2M, expected to fund to post-launch positive cash flow.
- Phase 3 CLARITY: LNZ100 71% achieved 3-line near vision improvement at 3 hours, 40% at 10 hours, well-tolerated over 30,000 patient days.
- SG&A expenses rose to $7.4M from $2.3M on pre-commercial planning and public company costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/0001815776-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/lenz-20240814.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer